## SUPPLEMENTAL MATERIAL

| Section                                         | Page Number |
|------------------------------------------------|-------------|
| 1. Study Protocol.                              | 2           |
| 2. Supplemental Table 1: Definitions.           | 4           |
| 3. Supplemental Table 2: PRISMA checklist.      | 6           |
| 4. Supplemental Table 3: Outcomes reported in randomized clinical trials. | 9-10        |
| 5. References                                   | 11-13       |
| 6. Supplemental Figures 1-5: Network Meta-Analysis | 14-18       |
Study Protocol

Methods for the literature search, data extraction, and analysis were specified in advance as outlined below:

Inclusion criteria

Studies meeting all of the following criteria were included:

1. Published studies irrespective of date of publication
2. Availability in the English language
3. Human subjects
4. Randomized control trial design
5. Clinical follow-up of any duration (including all-cause mortality, reinfarction, revascularization, cardiovascular (CV) mortality, need for repeat PCI, need for repeat coronary artery bypass grafting (CABG), stroke, contrast induced nephropathy (CIN) and major bleeding)

Exclusion criteria

Studies will be excluded if any of the following criteria are met:

1. Non-English language manuscripts
2. Studies without any clinical outcomes or control groups
3. Studies in animals
4. Imaging studies
5. Case reports, editorials, comments, letters, review articles, guidelines, or Non STEMI trials were also excluded from the analysis.
Systematic literature search

An electronic search of SCOPUS was performed in May 2015 for relevant randomized clinical trials. References of identified studies were manually searched for relevant publications. The search was independently implemented by two study investigators (NSB, PA) and verified by a third investigator (RK). The following search strategy was employed:

(TITLE-ABS-KEY("STEMI") OR TITLE-ABS-KEY("ST elevation myocardial infarction") OR TITLE-ABS-KEY("Acute myocardial infarction") AND TITLE-ABS-KEY("PCI") OR TITLE-ABS-KEY("Percutaneous coronary intervention") OR TITLE-ABS-KEY("angioplasty") AND TITLE-ABS-KEY("Culprit") OR TITLE-ABS-KEY("non-culprit") OR TITLE-ABS-KEY("complete revascularization")) AND (EXCLUDE(DOCTYPE, "re") OR EXCLUDE(DOCTYPE, "no") OR EXCLUDE(DOCTYPE, "ed") OR EXCLUDE(DOCTYPE, "le") OR EXCLUDE(DOCTYPE, "Undefined"))

Data selection and endpoints

The primary objective of this analysis was to evaluate the impact of various revascularization strategies versus the current standard, which is target/ culprit lesion revascularization, in patients presenting with ST-Elevation Myocardial Infarction. Data extracted from each trial included: 1) study details, including year, location, country, numbers of centers involved, duration of follow-up, number of patients, proportion of male patients, number of procedures, angiographic data, type of catheter-based therapy; 2) mortality outcomes, including all-cause, cardiovascular and non-cardiovascular mortality at end of reported follow up; 3) hemodynamic outcomes including technical success, presence of hemodynamic instability both before and after catheter-based
interventions, presence and improvement of left ventricular dysfunction, and occurrence of
cardiac arrest prior to catheter-based intervention and peri-procedural and post-procedural
cardiac arrest, 4) safety outcomes including minor and major access site bleeding, hemoptysis,
bleeding at other sites, and intracranial bleeding. Multiple investigators performed data
extraction (NSB, PA, RK). All investigators involved in data extraction (NSB, PA, RK) also
checked for consistency before full-scale data extraction was carried out. All discrepancies in
data extraction were resolved by mutual consensus.

Statistical analysis

After the data elements were verified for accuracy, systematic and statistical analyses were
conducted using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, New Jersey) and
STATA, version 14.0 (StataCorp LP), respectively. We used random effects modeling for all
analyses. We assessed for heterogeneity using the I² test (I² >50% with p-value < 0.05
considered as evidence of significant heterogeneity). We also performed a pre-specified sub-
group analysis to assess the role of Fractional flow reserve (FFR) in patients undergoing
complete revascularization (CR). Publication bias for the primary outcome was assessed using
the funnel plot and Eggers regression method and was considered significant if the one tailed p-
value was < 0.05. If significant publication bias was present, corrected estimates were calculated
using the Duval and Tweedie trim and fill method. The analysis was reported in accordance with
the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines.
### Table S1: Definitions

In all instances, the authors’ definition of the below mentioned characteristics was used. Where the definition has evolved since the time of publication or there were multiple interpretations, we used the following definitions:

| Characteristic                                      | Definition                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Follow-up                                           | Follow-up was measured in patients per 100 person years. This number was derived by multiplying the mean or median follow-up in months (as stated by authors) by the numbers of patients and then dividing by 12.                                                                                           |
| Number of procedures                                | Defined as being the same as the number of patients unless stated otherwise by the authors.                                                                                                                                                                                                                                               |
| Multi-vessel coronary artery disease                | Flow limiting coronary artery disease in ≥ 1 non-culprit epicardial coronary artery as defined by authors or > 50% obstruction by angiogram or Fractional Flow Reserve (FFR) < 0.8 in staged left heart catheterization.                                                                                                         |
| ST-elevation myocardial infarction                  | As defined by authors or ACC/AHA/SCAI or ESC consensus statement.                                                                                                                                                                                                                                                                       |
| Hemodynamic instability                             | Defined as patients with a systolic blood pressure less than 90 mmHg, a systolic blood pressure drop greater than 40mmHg drop for 15 minutes or more, or exhibiting a requirement for inotropic or vasopressor support. Shock index ≥1 was also used to define hemodynamic instability where the authors stated individual patients’ heart rate and blood pressure readings. Additionally, any patients described as being hemodynamically unstable by the authors (without a definition) and patients who had experienced cardiac arrest immediately prior to the procedure were also defined as being hemodynamically unstable. |
| Complete revascularization                          | Revascularization of the culprit artery and all flow-limiting epicardial coronary arteries.                                                                                                                                                                                                                                              |
| Staged revascularization                            | Revascularization of the culprit artery with later elective revascularization of all flow-limiting epicardial coronary arteries.                                                                                                                                                                                                        |
| Culprit lesion revascularization                    | Revascularization of culprit artery only.                                                                                                                                                                                                                                                                                             |
| Re-infarction                                       | As defined by ACC/AHA/SCAI guidelines or as defined by authors.                                                                                                                                                                                                                                                                       |
| In-stent thrombosis                                 | Defined as either angiographically confirmed partial or complete occlusion of stent or repeat myocardial infarction in the distribution of the revascularized vessel.                                                                                                                                                                         |
| Term                                            | Definition                                                                                                                                 |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| All-cause mortality                             | All deaths till the end of the follow-up period after being discharged from the index hospitalization. Where follow-up beyond discharge was not reported, this was the same as survival to discharge. The cause of death was further sub-divided into cardiovascular mortality and non-cardiovascular mortality. Where the cause of death could not be defined, the death was counted towards all-cause mortality without being included in the ‘cardiovascular mortality’ or ‘non-cardiovascular mortality’ sub-groups. |
| Major adverse cardiac event (MACE)             | Due to the heterogeneity in definitions amongst the included trials we defined MACE as follows: mortality including all-cause death, any new myocardial infarction (fatal and non-fatal myocardial infarctions), and revascularization with either percutaneous coronary intervention or coronary artery bypass grafting. |
| Cardiovascular mortality                        | Death due to ventricular failure, myocardial infarction, or cardiac arrest till the end of the follow-up period.                              |
| Non-cardiovascular mortality                    | Death from all causes aside from those listed in ‘cardiovascular mortality’.                                                             |
| Major bleeding                                  | Major bleeding was defined as follows: major visceral bleeding as defined by authors (including intracranial hemorrhage); any bleeding requiring operative intervention or transfusion of at least two units of packed red blood cells; bleeding leading to shock as defined above. |
| Minor bleeding                                  | Any other bleeding event that was not considered major bleeding.                                                                        |
| Contrast-induced nephropathy (CIN)             | Defined as the worsening of renal function after administration of radioactive contrast material. Per SCAI guidelines, CIN was defined as increase in serum baseline creatinine over 48 hours by >25% or an absolute increase of 0.25-0.5 mg/dl.¹² |
| Stroke                                          | Any new focal neurologic deficit of suspected vascular origin persisting beyond 24 hours or as defined by authors.                     |

Table S2: PRISMA checklist
| Section/Topic    | # | Checklist Item                                                                 | Reported on Page # |
|-----------------|---|-------------------------------------------------------------------------------|-------------------|
| TITLE           |   |                                                                               |                   |
| Title           | 1 | Identify the report as a systematic review, meta-analysis, or both.           | 1                 |
| ABSTRACT        |   |                                                                               |                   |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2                 |
| INTRODUCTION    |   |                                                                               |                   |
| Rationale       | 3 | Describe the rationale for the review in the context of what is already known. | 4-5               |
| Objectives      | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4-5               |
| METHODS         |   |                                                                               |                   |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 6-8 and Appendix Section 1 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 6-8 and Appendix Section 1 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 6-8 and 6-8 and Appendix Section 1 |
| Search          | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 6-8 and Appendix Section 1 |
| Section/Topic                          | # | Checklist Item                                                                                                                                                                                                 | Reported on Page # |
|---------------------------------------|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Study selection                       | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                               | 6-8 and Appendix Section 1 |
| Data collection process               | 10| Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                | 6-8 and Appendix Section 1 |
| Data items                            | 11| List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                   | 6-8 and Appendix Section 1 |
| Risk of bias in individual studies    | 12| Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6-8 and Appendix Section 1 |
| Summary measures                      | 13| State the principal summary measures (e.g., risk ratio, difference in means).                                                                                                                                     | 6-8 and Appendix Section 1 |
| Synthesis of results                  | 14| Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.                                                                | 6-8 and Appendix Section 1 |
| Risk of bias across studies           | 15| Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).                                                                          | 6-8 and Appendix Section 1 |
| Additional analyses                   | 16| Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                               | 6-8 and Appendix Section 1 |

**RESULTS**

| Study selection                       | 17| Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                | 9 |

7
| Study characteristics       | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. |
|----------------------------|----|----------------------------------------------------------------------------------------------------------------------------------|
| Risk of bias within studies| 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                          |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. |
| Synthesis of results       | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency.                          |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15).                                                  |
| Additional analysis        | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).             |

**DISCUSSION**

| Summary of evidence       | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). |
|----------------------------|----|----------------------------------------------------------------------------------------------------------------------------------|
| Limitations                | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). |
| Conclusions                | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research.          |

**FUNDING**

| Funding                    | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. |

*From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097*
Table S3: Outcomes reported in randomized clinical trials

| Study | MACE Definition | CV mortality | All-cause Mortality | In-hospital death | Non-Fatal MI | MI | Reinfarction | Refractory Angina | Repeat Revascularization | PTCA or CABG | PTCA | CABG | Rehospitalization for ACS | CIN | Stroke | Major Bleeding |
|-------|----------------|--------------|--------------------|-------------------|--------------|----|------------|------------------|-----------------------|---------------|------|------|------------------------|-----|--------|------------------|
| CvLPRIT/ Gershlick et al (3) | All-cause mortality, recurrent MI, HF, and repeat revascularization | * | * | NR | NR | * | * | NR | * | NR | NR | NR | NR | NR | * | * | * |
| DANAM3- PRIMULTI/ Engstrom et al (4) | All-cause mortality, non-fatal MI and ischemia-driven revascularization | * | * | NR | * | NR | NR | NR | * | Calculated | Calculated | NR | * | * | * |
| Tarasov et al (5) | CV mortality, MI, target vessel revascularization | * | * | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| REAME/ Wald et al (6) | As above | * | * | NR | * | NR | NR | * | * | NR | NR | NR | NR | NR | * | * | * |
| Dambrink et al (7) | All-cause mortality, non-fatal MI, and additional unplanned revascularization | NR | Calculated | NR | NR | * | NR | NR | * | * | * | * | NR | NR | NR | NR | NR |
| Politi et al (8) | All-cause mortality, in-hospital mortality, reinfarction, rehospitalization for ACS, repeat revascularization | * | * | * | NR | NR | * | NR | * | * | * | * | * | NR | NR | NR | NR |
| HELP-AMI/ Di Mario et al (9) | Not defined but reported | NR | * | * | NR | * | NR | NR | NR | * | NR | NR | NR | NR | NR | NR | NR |
| PRIMA/ Ochala et al (10) | All-cause mortality, repeat MI, target vessel revascularization | * | * | NR | NR | NR | * | NR | * | Calculated | * | * | NR | NR | NR | NR | * |

MACE: Major Adverse Cardiovascular Events; MI: Myocardial infarction; NR: Not reported; CV: Cardiovascular; PTCA: Percutaneous Transluminal Coronary Angioplasty; CABG: Coronary Artery Bypass Grafting; ACS: Acute Coronary Syndrome; CIN: Contrast-induced Nephropathy; CvLPRIT: Randomized Trial of
Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease;
PRAMI: Randomized Trial of Preventive Angioplasty in Myocardial Infarction; HELP-AMI: Single vs. multivessel treatment during primary angioplasty: results of the multicenter randomized HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction; DANAMI3-PRIMULTI: The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction PRImary PCI in MULTIvessel Disease; PRIMA: PRIMArY percutaneous intervention in acute myocardial infarction.
References

1. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013; 82: E1-27.

2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blöhmstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33: 2569-619.

3. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M16, Hall R, Swanton H, McCann GP. Randomized Trial of
Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease: The CvLPRIT Trial. *J Am Coll Cardiol* 2015; 65: 963-72.

4. Engstrøm T. The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction. 2015. http://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=76552a6208024fc89e0425c80836c30b.

5. Tarasov RS, Ganyukov VI, Protopopov AV, Barbarash OL, Barbarash LS. Six month results of randomized clinical trial: Multivessel stenting versus staged revascularization for ST-elevation myocardial infarction patients with second generation drug eluting stents. *Clinical Medicine Research.* 2014; 3: 125-9.

6. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. *N Engl J Med.* 2013; 369: 1115-23.

7. Dambrink JH, Debrauwere JP, van 't Hof AW, Ottervanger JP, Gosselink AT, Hoortjte JC, de Boer MJ, Suryapranata H. Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines? *EuroIntervention.* 2010; 5: 968-75.

8. Politi L, Sgura F, Rossi R, Monopoli D, Guerri E, Leuzzi C, Bursi F, Sangiorgi GM, Modena MG. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. *Heart.* 2010; 96: 662-7.

9. Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, Emanuela P, Stefano DS, Angelo R, Stefania C, Anna F, Carmelo C, Antonio C, Monzini N, Bonardi MA. Single vs multivessel treatment during primary angioplasty: results of the multicentre
randomised HEpacoat for cuLPrir or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent.* 2004; 6: 128-33.

10. Ochala A, Smolka GA, Wojakowski W, Dudek D, Dziewierz A, Krolikowski Z, Gasior Z, Tendera M. The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. *The J Invasive Cardiol.* 2004; 16: 699-702.
Figure S1: Network for treatment comparison for primary outcome.
The solid blue circle represents the treatment. The size of the circle corresponds to the total sample size of treatment from all included trials. The solid black line represents direct treatment comparisons. The thickness of line corresponds to total sample size assessing the comparison.

CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization at index angiogram; CL = culprit lesion revascularization only at index angiogram.
**Figure S2: Contribution plot for revascularization strategy in ST-elevation myocardial infarction network.**

The size of each square is proportional to the weight attached to each direct summary effect (horizontal axis) for the estimation of each network summary effects (vertical axis). The numbers re-express the weights as percentages.

|                | CL vs CR | CL vs SR | CR vs SR |
|----------------|----------|----------|----------|
| Mixed estimates| 87.6     | 62.5     | 62.5     |
| CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization at index angiogram; CL = culprit lesion revascularization only at index angiogram.
Figure S3: Predictive interval plot on a logarithmic scale.
The black solid lines represent the confidence intervals for summary odds ratios for each comparison and the red dashed lines the respective predictive intervals. The blue line is the line of no effect (odds ratio equal to 1).

CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization at index angiogram; CL = culprit lesion revascularization only at index angiogram
Figure S4: Network Forest plot on a logarithmic scale.
The blue solid lines represent the confidence intervals for log odds ratios for each comparison in individual studies and the green solid lines represent log odds ratio within study design and blue solid line represents respective overall log odds ratio using consistency and inconsistency models. The black dashed line is no effect (odds ratio equal to 1).

CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization at index angiogram; CL = culprit lesion revascularization only at index angiogram
Figure S5: Comparison-adjusted funnel plot.
The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective comparison-specific pooled effect estimates. Different colors correspond to different comparisons.

CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization at index angiogram; CL = culprit lesion revascularization only at index angiogram